You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Advances in the Treatment of Glioblastoma Multiforme: Is There a Role for Immune Checkpoint Inhibitors?

  • Authors: Michael Lim, MD (Chair/Planner); Gavin P. Dunn, MD, PhD, FAANS; Peter E. Fecci, MD, PhD
  • CME / CE Released: 4/24/2017
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 4/24/2018
Start Activity


Target Audience and Goal Statement

This activity is primarily intended for neuro-oncologists, neurosurgeons, neuropathologists, and radiology and medical oncologists. NPs/PAs, oncology nurses, and clinical oncology pharmacists will also find this material beneficial. No prerequisites required.

The goal of this activity is to provide clinicians with the most up to date evidence on the role of the immune system and immunotherapy in glioblastoma multiforme (GBM). This activity will also present the latest advances regarding the use of checkpoint inhibitors as a treatment strategy for GBM, as well as considerations for the use of these therapies in clinical practice.

Upon completion of this activity, participants will be able to:

  1. Describe the latest evidence providing rationale for targeting the immune system in the treatment of GBM.
  2. Evaluate results of ongoing clinical trials examining immunotherapy agents as part of GBM treatment paradigms.
  3. Recognize strategies to manage the unique adverse events related to the use of immunotherapy in GBM.


Disclosures

DISCLAIMER
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

CONFIDENTIALITY DISCLAIMER FOR CME ACTIVITY PARTICIPANT
I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Johns Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person’s health or treatment that identifies the person. I also understand that while I am participating in this capacity I will be treated as a temporary member of Johns Hopkins for purposes of the Privacy Regulations only.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: [email protected]

"The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only."

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/09)

THE INSTITUTE FOR JOHNS HOPKINS NURSING MISSION STATEMENT
The mission of The Institute for Johns Hopkins Nursing is to share the innovations of Johns Hopkins Nursing in practice, education, and research—locally, nationally, and globally.
Our goal in continuing nursing education is to bring you activities that reflect the expertise and creativity of Johns Hopkins Nursing. Our service values are quality, integrity, flexibility, and personal attentiveness. We appreciate your thoughts and welcome your concerns—please feel free to e-mail us: [email protected]

Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME.

Policy on Faculty and Provider Disclosure
It is the policy of the Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the instructional materials.

The following relationships have been reported for this activity:

Participating Faculty Disclosures
No speakers have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).


Faculty

  • Michael Lim, MD (Chair/Planner)

    Associate Professor, Neurosurgery, Oncology, Radiation Oncology, Institute of Nanobiotechnology, Director, Brain Tumor Immunotherapy Program; Director, Metastatic Brain Tumor Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

    Disclosures

    Disclosure: Dr. Lim reports receiving research grants/research support from and serving as a consultant for Agenus Inc and Bristol-Myers Squibb Company; receiving grants/research support from Accuray Incorporated, Arbor Pharmaceuticals, Celldex Therapeutics, and ImmunoCellular Therapeutics Ltd; serving as a consultant for Boston Biomedical and Oncor Inc; and, receiving honoraria from Regeneron Pharmaceuticals Inc and Stryker Corporation.

  • Gavin P. Dunn, MD, PhD, FAANS

    Assistant Professor of Neurological Surgery, Pathology and Immunology, Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, Missouri

    Disclosures

    Disclosure: Dr. Dunn has no relevant financial relationships to disclose.

  • Peter E. Fecci, MD, PhD

    Assistant Professor, Neurosurgery, Director, Brain Tumor Immunotherapy Program, Associate Residency Program Director, Duke University Medical Center, Durham, North Carolina

    Disclosures

    Disclosure: Dr. Fecci has no relevant financial relationships to disclose.

Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).


Accreditation Statements

    For Physicians

  • The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine's CME program. CME collects only the information necessary to provide you with the services that you request.

    Jointly provided by Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing.

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s) TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

    For Nurses

  • The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    This 1.0 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Claim only those contact hours actually spent in the activity. Statements will be awarded for this educational activity until April 24, 2018.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Advances in the Treatment of Glioblastoma Multiforme: Is There a Role for Immune Checkpoint Inhibitors?

Authors: Michael Lim, MD (Chair/Planner); Gavin P. Dunn, MD, PhD, FAANS; Peter E. Fecci, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / CE Released: 4/24/2017

Valid for credit through: 4/24/2018

processing....

Before you begin, please answer the questions in this brief questionnaire.
Thank you for completing the pre-activity questionnaire.

  • Print